En Español
The U.S. Food and Drug Administration (FDA) recently revealed they have received complaints related to two diabetes drugs in the SGLT2 inhibitor classification. These drugs are routinely used to treat Type II diabetes. The concerns filed with the federal agency are in regard to the relationship between bone loss and fractures and the drugs Invokana (Invokamet).
The drug, Invokana does carry a warning label on the product warning of the potential side effect of bone fractures. The FDA will now require the makers of Invokana to have stronger warnings to indicate the high risks and seriousness of potential bone fractures or bone loss while taking the medication to treat Type II diabetes.
According to documents from the FDA, a patient has this increased risk after even a short time on the medication. In just 12 weeks after starting Invokana, bone loss can occur. The FDA indicated that the most common types of fractures were in the upper extremities of the body and that fractures are more common in what it calls low-trauma injuries such as falls that occur while walking.
The federal agency cited a recent study involving some 714 elderly patients that had a marked lesser bone density around the hips and spine of those who were prescribed an SGLT2 inhibitor drug.
There have been numerous lawsuits against the makers of Invokana or Invokamet that allege health issues arising after taking the drug such as kidney failure, ketoacidosis, as well as strokes, heart attacks,
If you or someone you love has suffered from ketoacidosis, heart problems, kidney problems, or any other serious health condition while taking Invokana, you may have a case for a complete financial recovery.
At the law offices of John Foy & Associates, we can help you determine if your case qualifies. Contact us today at 404-620-3484 to schedule a free consultation.
